导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -9.35% | 3762/4773 |
| 近一周 | -2.08% | 2282/5458 |
| 近一月 | -3.91% | 2535/5421 |
| 近一季 | -3.61% | 2040/5205 |
| 近半年 | -12.12% | 3798/4920 |
| 近一年 | -8.61% | 3371/4361 |
| 近两年 | 17.81% | 2702/2954 |
| 近三年 | -1.06% | 1956/2253 |
| 成立以来 | 109.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.10% 2128/4961 |
-7.68% 3791/5312 |
- - |
- - |
| 2025 | 8.78% 2893/4813 |
1.39% 1633/3635 |
-2.89% 3388/4076 |
9.37% 3361/4524 |
1.01% 1602/4813 |
| 2024 | 9.70% 1451/3463 |
5.77% 334/2808 |
-4.78% 1552/3014 |
16.10% 1533/3129 |
-6.19% 2629/3463 |
| 2023 | -8.63% 1036/2656 |
6.18% 715/2280 |
-6.79% 1709/2385 |
-0.70% 436/2515 |
-7.02% 2019/2655 |
| 2022 | -18.11% 663/2207 |
-15.64% 1056/1919 |
6.51% 681/2016 |
-11.70% 563/2113 |
3.22% 745/2208 |
| 2021 | -11.97% 1118/1822 |
-0.98% 411/1255 |
-3.38% 1243/1330 |
-10.03% 1207/1466 |
2.27% 642/1822 |
| 2020 | 32.14% 490/1250 |
-13.56% 931/1028 |
14.63% 541/1067 |
12.55% 380/1164 |
18.50% 90/1184 |
| 2019 | 55.89% 69/1092 |
37.81% 70/754 |
1.51% 123/804 |
1.99% 335/850 |
9.26% 241/918 |
| 2018 | -24.96% 337/834 |
- - |
- - |
- - |
-8.61% 101/691 |
| 2017 | 45.84% 15/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.52% 176/605 |
- - |
- - |
- - |
- - |
| 2015 | 14.36% 144/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.84% 69/237 |
- - |
- - |
- - |
- - |
| 2013 | -4.81% 91/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.96% 80/140 |
- - |
- - |
- - |
- - |
| 2011 | -30.37% 92/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 工银深证红利ETF联接A VS. 长安沪深300非周期A(740101) |